Kinase Inhibitors Produced Selective Changes in Established THC Tolerance

A behavioral experiment found that kinase inhibitors differed in their ability to reverse established THC tolerance. PKA inhibition affected all measured behaviors, while other inhibitor classes produced selective or null results.

Reversal was the question being tested

The study examined signaling pathways involved in expression of tolerance after repeated THC administration. This differs from asking whether an intervention prevents tolerance during its development. The investigators compared inhibitors directed at several kinase pathways across multiple THC-related behavioral measures.

The positive and null findings differed

PKA inhibition reversed tolerance across the measures described, but the effective inhibitor doses and time courses varied by behavior. Src tyrosine kinase inhibition reversed tolerance only to THC-related hypoactivity. The tested PKG- and PKC-directed inhibitors did not reverse tolerance on any behavioral measure. Those null results are part of the study's central pattern.

Behavioral effects do not measure enzyme activity directly

An inhibitor changing a tolerated behavior supports involvement of a signaling pathway under those conditions. It does not, by itself, show that chronic THC increased the pathway's overall activity throughout the brain. Direct enzyme assays and behavioral intervention experiments address related but different questions.

The evidence supports selective pathway involvement, rather than a practical tolerance-reset regimen. The abstract does not establish human efficacy, consumer dosing or safety for these experimental interventions. Any interpretation should preserve the measured behavior and the timing of inhibition rather than generalizing the PKA finding to every consequence of cannabis use.

Related: interpreting cannabis tolerance claims.

Research cited

Bass CE; Welch SP; Martin BR. Reversal of delta 9-tetrahydrocannabinol-induced tolerance by specific kinase inhibitors. European journal of pharmacology (2004). doi:10.1016/j.ejphar.2004.06.009. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

How Did a Laboratory Study Decide That a Detected Drug Was Non-Prescribed?

A laboratory can identify a drug while relying on outside information to classify its prescription status. A national urine-testing study combined analytical results with medication information supplied by the ordering clinician. Two information streams McClure and colleagues analyzed 231,228 test-result sets from 144,535 patients tested for both opioids and benzodiazepines….

Spread the love

Read Article: How Did a Laboratory Study Decide That a Detected Drug Was Non-Prescribed?

How Did a Stress-Management Trial Protocol Handle Medication Changes?

When a study evaluates psychological treatment, medication changes can complicate attribution of improvement. The 2017 Seren@ctif protocol described how investigators planned to address this issue in a trial of adjustment disorder with anxiety. The planned comparison Servant and colleagues proposed three randomized groups receiving computer-based stress management, an equivalent face-to-face…

Spread the love

Read Article: How Did a Stress-Management Trial Protocol Handle Medication Changes?

What Evidence Supports Extending Lipid Rescue to a Different Poison?

A treatment that appears useful for one toxicant raises a separate scientific question when proposed for another. Eisenkraft and Falk’s 2016 review of lipid emulsion and chemical-agent poisoning provides an example of that evidence gap. Several evidence types The authors discussed proposed lipid-scavenging, metabolic, and cardiovascular mechanisms. They reviewed laboratory…

Spread the love

Read Article: What Evidence Supports Extending Lipid Rescue to a Different Poison?

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us